Orphazyme's arimoclomol shows meaningful treatment effect in late-stage NPC study

Stock Information for LadRx

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About LadRx

LadRx Corporation Announces OTCQB Ticker Change to LADX
CytRx Corporation Relaunches as LadRx Corporation
European Patent Office Awards CytRx Key Patent
CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors
CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.
CytRx Partners with Oncology Development Expert to Advance LADR Platform
CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.